With a Food and Drug Administration public hearing scheduled in less than two weeks to debate the merits of pharmaceutical direct-to-consumer advertising, attendees of the "DTC at the Turning Point"
conference were anxious to hear about the fate of the $4 billion industry. And the consensus was the only thing certain was change.
Read the whole story at AdAge.com, October 20, 2005 »
